Traders Purchase Large Volume of Cytokinetics Call Options (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) was the target of some unusual options trading activity on Monday. Traders acquired 5,619 call options on the stock. This represents an increase of approximately 103% compared to the average volume of 2,772 call options.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Morgan Stanley restated an “overweight” rating and issued a $71.00 price target on shares of Cytokinetics in a report on Monday. Bank of America upped their target price on shares of Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research note on Thursday, October 2nd. Wall Street Zen lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. HC Wainwright boosted their price objective on shares of Cytokinetics from $120.00 to $136.00 and gave the stock a “buy” rating in a report on Monday. Finally, Needham & Company LLC upped their price objective on shares of Cytokinetics from $72.00 to $84.00 and gave the company a “buy” rating in a research report on Monday. Fifteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $83.61.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval of Myqorzo turns Cytokinetics into a commercial-stage biotech with a clear cardiology franchise and a long-term growth runway. This is the primary catalyst lifting the stock. Cytokinetics Wins FDA Nod For Heart Drug Myqorzo Zacks: Cytokinetics Wins FDA Approval
• Positive Sentiment: Analysts are raising price targets across the board (Barclays, Morgan Stanley, Needham, Citizens JMP, BofA), reflecting higher revenue and commercial assumptions post-approval — this supports additional buying and sets higher valuation anchors. Links to representative reports: Barclays, Morgan Stanley, BofA. Barclays raises PT to $87 Morgan Stanley raises PT to $71 BofA raises PT to $64
• Positive Sentiment: Product label differences give Myqorzo practical commercial advantages versus the incumbent (Camzyos) — notably flexible dosing that may ease prescribing and titration, supporting adoption and patient preference goals. Seeking Alpha: Small Label Differences With Big Commercial Stakes
• Positive Sentiment: Unusual options flow: a big spike in call buying signals increased speculative and/or institutional bullish interest that can amplify short-term upside and liquidity. (Internal trading item)
• Neutral Sentiment: Company-management commentary and the full conference-transcript provide color on commercialization plans and launch cadence; useful for modeling uptake but not immediately price-moving beyond the approval itself. Seeking Alpha: MYQORZO approval transcript
• Negative Sentiment: Management expects gradual adoption (targeting mid‑high 20% category penetration by end‑2026) and anticipates reliance on patient-assistance programs — this implies a ramp that may be slower than some investors hope and could pressure near-term revenue/margin visibility. Seeking Alpha: Small Label Differences With Big Commercial Stakes

Cytokinetics Price Performance

Shares of CYTK stock opened at $65.60 on Tuesday. The firm has a market cap of $8.02 billion, a P/E ratio of -10.43 and a beta of 0.58. Cytokinetics has a 1-year low of $29.31 and a 1-year high of $70.98. The firm has a fifty day moving average of $62.83 and a two-hundred day moving average of $48.88.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analyst estimates of $6.05 million. The business’s revenue for the quarter was up 318.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.36) EPS. On average, sell-side analysts expect that Cytokinetics will post -5.24 EPS for the current year.

Insider Buying and Selling at Cytokinetics

In other news, Director Edward M. Md Kaye sold 28,064 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $66.72, for a total value of $1,872,430.08. Following the completion of the sale, the director owned 9,977 shares of the company’s stock, valued at $665,665.44. This represents a 73.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert I. Blum sold 5,000 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $55.05, for a total value of $275,250.00. Following the completion of the sale, the chief executive officer owned 368,108 shares of the company’s stock, valued at approximately $20,264,345.40. This trade represents a 1.34% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 148,494 shares of company stock worth $9,488,218. Corporate insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new stake in shares of Cytokinetics during the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC bought a new stake in Cytokinetics during the third quarter valued at $32,000. Johnson Financial Group Inc. acquired a new stake in shares of Cytokinetics during the third quarter worth $40,000. EverSource Wealth Advisors LLC raised its holdings in shares of Cytokinetics by 723.7% during the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 673 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Cytokinetics in the 3rd quarter worth about $45,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.